Carlyle Group's acquisition of bluebird bio for $3 per share offers a potential but unlikely $600 million sales milestone by ...

Shares of bluebird bio (NASDAQ:BLUE) continued their downward descent Monday in the wake of news that the company has agreed to be taken private by Carlyle Group (NASDAQ:CG) and SK Capital ...

bluebird stockholders to receive $3.00 per share in cash and ... in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene ...

Bluebird Bio (NASDAQ: BLUE) said its planned acquisition by two investment firms is, according to its board, “in the best interest of stockholders”—but enough of them felt otherwise on ...

The adjustment accounts for anticipated near-term dilution and reflects the firm’s belief in the long-term potential of bluebird bio’s lentiviral vector-based cell therapies. Baird suggests that ...

bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, contingent upon offer conditions ...

bluebird stockholders to receive $3.00 per share ... analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

Few filmmakers have as varied a CV as Richard Linklater’s. From the box office hit School of Rock to his experiments with rotoscope, he is indefatigably curious and surprisingly consistent ...

U.S. Gene Therapy Market Report Highlights: • By type, the gene silencing segment dominated the market in 2024. • By vector, the viral vector segment led the market in 2024. • By therapeutic area, the ...